Potential Serum Markers for Monitoring the Progression of Hepatitis B Virus-Associated Chronic Hepatic Lesions to Liver Cirrhosis.
- Author:
Cheng WU
1
;
Lijie LIU
;
Peng ZHAO
;
Dan TANG
;
Dingkang YAO
;
Liang ZHU
;
Zhiqiang WANG
Author Information
- Publication Type:Original Article
- Keywords: Chronic hepatic lesions; Proteomics; Diagnosis; Surface-enhanced laser desorption/ionization; Biological markers
- MeSH: Adult; Aged; Biomarkers/*blood; Carcinoma, Hepatocellular/*virology; Disease Progression; Female; Hepatitis B virus; Hepatitis B, Chronic/*blood/complications; Humans; Liver Cirrhosis/*blood/pathology/virology; Liver Neoplasms/*virology; Male; Middle Aged; Protein Array Analysis; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Young Adult
- From:Gut and Liver 2015;9(5):665-671
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: To screen for serum protein/peptide biomarkers of hepatitis B virus (HBV)-associated chronic hepatic lesions in an attempt to profile the progression of HBV-associated chronic hepatic lesions using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) techniques. METHODS: Using SELDI-TOF MS, serum protein/peptide profiles on the CM10 ProteinChip arrays were obtained from a training group including 26 HBV-associated hepatocellular carcinoma patients with liver cirrhosis (LC), 30 HBV-associated LC patients, 85 patients at different stages of liver fibrosis, and 30 asymptomatic HBV carriers. The most valuable SELDI peak for predicting the progression to LC in HBV-infected patients was identified. RESULTS: A SELDI peak of M/Z 5805 with value for predicting LC in HBV-infected patients was found and was identified as a peptide of the C-terminal fraction of the fibrinogen alpha-chain precursor, isoform 1. CONCLUSIONS: The peptide of the C-terminal fraction of the fibrinogen alpha-chain precursor, isoform 1 with M/Z 5805, may be a serological biomarker for progression to LC in HBV-infected patients.
